Supergen, Inc. (MM) (NASDAQ:SUPG)
Historical Stock Chart
5 Years : From May 2012 to May 2017
SuperGen, Inc. (NASDAQ: SUPG), a pharmaceutical company dedicated to the
discovery and development of novel cancer therapies, announced it
anticipates that it will begin operating under the name Astex
Pharmaceuticals, Inc. on September 12, 2011. The new name follows the
previously announced closing of its acquisition of Astex Therapeutics
Limited, a privately held, UK-based biotechnology company developing
targeted therapies. Astex Pharmaceuticals, Inc. is expected to begin
trading on NASDAQ under the symbol ASTX on September 12, 2011.
Astex Therapeutics Limited became a wholly owned subsidiary of SuperGen,
Inc. on July 20, 2011. Further information about this transaction is
available at http://www.astex-supergen.com,
or in the investor relations section of the SuperGen website at http://www.supergen.com.
SuperGen is a pharmaceutical company dedicated to the discovery and
development of novel cancer therapeutics in epigenetic and cell
signaling modulation. The Company develops products through biochemical
and clinical proof of concept to partner for further development and
commercialization. SuperGen developed Dacogen® and receives significant
royalties on global sales.
For more information about SuperGen, please visit http://www.supergen.com.
Note on Forward-Looking Statements
This press release contains certain forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934, including but not limited to,
statements regarding the expectation that the Company will change its
name and ticker symbol. These and other forward-looking statements
involve certain risks and uncertainties that could cause actual results
to differ materially from those indicated in such forward-looking
statements, including, but not limited to, the ability of the Company to
change its name and its ticker symbol, and such other risks as
identified in the Company’s Annual Report on Form 10-K for the fiscal
year ended December 31, 2010, and the Company’s most recent Quarterly
Reports on Form 10-Q, each as filed with the SEC, which contain and
identify important factors that could cause the actual results to differ
materially from those contained in the forward-looking statements. The
Company assumes no obligation to update any forward-looking statement
contained in this press release.